Why this study matters
Cone-rod dystrophy is an inherited retinal disease in which cone cells—the photoreceptors important for detailed central vision, color vision, and daytime sight—are affected, often followed by rod cells, which support vision in dim light. Symptoms can include declining central vision, difficulty seeing at night (nyctalopia), and progressive retinal changes. Yet even when relatives carry the same disease-causing genetic variant, their experiences can be very different.
A 2026 study in Ophthalmic Genetics examines this challenge through a four-generation family carrying the same variant in the CRX gene. The findings show why a genetic result is essential for understanding an inherited retinal disease, but may not fully predict when symptoms will begin or how severe they will become.
CRX: a key regulator of photoreceptor function
The CRX gene provides instructions for a protein that helps switch on other genes needed for photoreceptor development and function. Changes in CRX can cause dominantly inherited retinal conditions, meaning a person needs to inherit only one altered copy of the gene to be at risk of disease.
The family in this study carried a frameshift variant called c.590del, p.(Pro197Argfs*22), abbreviated by the researchers as CRXP197Rfs. A frameshift changes how genetic instructions are read, producing an altered protein. This particular variant falls into a group of CRX changes known as Class III variants.
Six family members underwent genetic testing using a retinal dystrophy panel, with the result confirmed by Sanger sequencing. The researchers then followed carriers with detailed eye assessments, including visual-acuity testing, fundus autofluorescence imaging, optical coherence tomography (OCT), and full-field electroretinography (ffERG).
The same variant produced very different clinical pictures
Three relatives carried the identical CRXP197Rfs variant, but their clinical outcomes differed markedly.
The proband developed progressive loss of central vision and nyctalopia. Imaging showed outer-retinal atrophy, consistent with damage in the retinal layers containing photoreceptors and their supporting structures. ffERG testing, which measures the retina’s electrical responses to light, showed reduced responses. Together, these findings supported a cone-rod dystrophy phenotype.
In contrast, two other carriers remained asymptomatic as adults. They retained good visual acuity and had normal ffERG findings. However, more sensitive testing detected subtle changes: mild thinning of the outer nuclear layer on OCT and abnormal fundus autofluorescence. The outer nuclear layer contains photoreceptor cell bodies, while autofluorescence imaging can reveal changes in retinal tissue before they necessarily cause noticeable vision symptoms.
This contrast is especially important for families. It demonstrates variable expressivity—the concept that the same genetic variant can cause different degrees of disease in different people. In this family, the variant was associated with both symptomatic, progressive cone-rod dystrophy and much milder, clinically quiet retinal changes.
A dominant-negative mechanism helps explain the biology
The researchers also investigated how CRXP197Rfs affects CRX protein function. In laboratory experiments using human HEK293 cells, the altered protein lacked the ability to activate a rhodopsin-promoter reporter. Rhodopsin is a critical protein in rod photoreceptors, and the experiment tests whether CRX can help turn on relevant genetic programs.
Importantly, CRXP197Rfs did not simply fail to work on its own. It also suppressed the activity of normal, wild-type CRX in a dose-dependent fashion: greater amounts of the altered protein led to greater interference with the normal protein’s function. Tests in retinal explants from mice lacking their own Crx gene supported this result.
This is known as a dominant-negative effect. Rather than one working CRX copy being enough to maintain normal activity, the altered protein actively disrupts the function of the healthy protein. This mechanism provides a molecular explanation for why one altered CRX copy can lead to retinal disease.
Implications for treatment development
The dominant-negative finding has direct relevance for therapeutic strategy. Traditional gene augmentation aims to provide an additional functional copy of a gene. But when a mutant protein interferes with the healthy protein, simply adding more normal CRX may not fully address the problem.
The study instead supports an approach that combines mutant-allele knockdown with gene augmentation. In principle, this would reduce production of the harmful altered CRX protein while also restoring sufficient normal CRX activity. The research does not test such a treatment in people, but it identifies a biologically grounded direction for future therapeutic development.
The study also reinforces the value of longitudinal monitoring. Relatives with no current symptoms still showed subtle structural or autofluorescence changes, suggesting that multimodal retinal imaging can identify disease-related changes that may not be apparent through visual acuity or symptoms alone.
Looking ahead
This family study adds to the growing understanding that inherited retinal diseases cannot always be forecast from a genetic result alone. For CRX-associated cone-rod dystrophy, the specific variant matters, but so does the wide variation in how that variant is expressed within a family.
Future research will need to clarify why some carriers develop earlier or more severe disease while others remain minimally affected. At the same time, defining the dominant-negative behavior of variants such as CRXP197Rfs helps move the field toward more precise treatment designs—approaches aimed not only at replacing missing gene function, but also at addressing the harmful effects of an altered protein.